See more : Zacapa Resources Ltd. (ZACAF) Income Statement Analysis – Financial Results
Complete financial analysis of Alterity Therapeutics Limited (ATHE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alterity Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- South Jersey Industries, Inc. (SJI) Income Statement Analysis – Financial Results
- Investor AB (publ) (IVSXF) Income Statement Analysis – Financial Results
- Metals Exploration plc (MTL.L) Income Statement Analysis – Financial Results
- Unite Group Plc (UTGPF) Income Statement Analysis – Financial Results
- Future Consumer Limited (FCONSUMER.NS) Income Statement Analysis – Financial Results
Alterity Therapeutics Limited (ATHE)
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.02M | 3.92M | 5.12M | 4.34M | 0.00 | 108.54K | 201.17K | 132.40K | 142.66K | 176.84K | 363.78K | 150.87K | 186.66K | 156.14K | 215.01K | 428.19K | 492.00K | 507.04K | 762.49K | 2.64M | 2.31M | 1.81M | 794.39K | 516.18K | 78.76K | 0.00 | 0.00 |
| Cost of Revenue | 214.30K | 285.07K | 364.67K | 360.03K | 112.43K | 29.70K | 21.80K | 21.33K | 22.81K | 257.30K | -7.85M | -4.34M | 0.00 | 399.24K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.80M | 3.63M | 4.76M | 3.98M | -112.43K | 78.84K | 179.38K | 111.07K | 119.85K | -80.46K | 8.21M | 4.49M | 186.66K | -243.10K | 215.01K | 428.19K | 492.00K | 507.04K | 762.49K | 2.64M | 2.31M | 1.81M | 794.39K | 516.18K | 78.76K | 0.00 | 0.00 |
| Gross Profit Ratio | 94.67% | 92.72% | 92.88% | 91.70% | 0.00% | 72.64% | 89.16% | 83.89% | 84.01% | -45.50% | 2,256.66% | 2,975.15% | 100.00% | -155.70% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 18.64M | 13.20M | 14.75M | 12.28M | 10.10M | 12.98M | 6.70M | 5.70M | 9.59M | 12.30M | 14.91M | 7.95M | 4.23M | 2.33M | 87.99K | 2.22M | 5.77M | 4.49M | 7.62M | 7.66M | 5.20M | 1.86M | 2.48M | 2.38M | 421.93K | 0.00 | 0.00 |
| General & Administrative | 4.77M | 4.99M | 5.43M | 6.85M | 3.33M | 4.28M | 4.32M | 3.95M | 3.59M | 4.06M | 3.09M | 3.12M | 506.93K | 3.57M | 3.92M | 5.27M | 6.30M | 6.73M | 4.31M | 8.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -9.67K | 51.48K | 79.33K | 21.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 87.85K | 358.60K | 136.19K | 124.97K | 110.65K | 130.09K | 222.68K | 141.34K | 215.41K | 134.83K | 441.12K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.76M | 5.04M | 5.51M | 6.87M | 3.33M | 4.28M | 4.32M | 3.95M | 3.59M | 4.15M | 3.45M | 3.25M | 631.90K | 3.68M | 4.05M | 5.49M | 7.43M | 6.95M | 4.44M | 5.63M | 4.81M | 2.57M | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | -282.96K | -364.67K | -360.03K | -3.36M | -4.79M | 2.90M | -241.89K | -241.95K | -170.98K | -507.32K | -420.95K | 19.62K | 31.58K | 975.99K | 1.01M | 7.46M | 58.57K | 118.27K | 6.79M | 6.00M | 3.75M | 3.31M | 1.14M | 0.00 | -80.00K | -690.00 |
| Operating Expenses | 23.41M | 17.35M | 17.54M | 19.31M | 10.07M | 12.47M | 11.10M | 6.77M | 8.49M | 10.61M | 12.41M | 7.64M | 7.85M | 6.04M | 5.12M | 8.72M | 13.23M | 11.50M | 12.18M | 14.45M | 11.20M | 5.60M | 5.79M | 3.52M | 421.93K | -80.00K | -690.00 |
| Cost & Expenses | 23.62M | 17.63M | 17.90M | 19.67M | 10.07M | 12.47M | 11.10M | 6.77M | 8.49M | 10.61M | 12.41M | 7.64M | 7.85M | 6.44M | 5.12M | 8.72M | 13.23M | 11.50M | 12.18M | 14.45M | 11.20M | 5.60M | 5.79M | 3.52M | 421.93K | -80.00K | -690.00 |
| Interest Income | 268.42K | 16.44K | 2.50K | 20.68K | 17.12K | 108.54K | 201.17K | 132.40K | 142.66K | 0.00 | 29.98K | 150.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 888.51K | 210.04K | 0.00 | 226.84K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.98K | 17.68K | 11.54K | 3.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 35.34K | 102.26K | 54.21K | 75.37K | 112.43K | 29.70K | 21.80K | 21.33K | 22.81K | 31.59K | 22.38K | 23.13K | 19.62K | 31.58K | 35.29K | 34.19K | 25.40K | 58.57K | 118.27K | 1.16M | 1.19M | 1.18M | 1.16M | 1.14M | 0.00 | 0.00 | 0.00 |
| EBITDA | -19.57M | -17.51M | -17.39M | -19.36M | -13.34M | -12.77M | -11.37M | -6.86M | -8.56M | -10.57M | -12.53M | -7.76M | -5.21M | -6.40M | -4.87M | -7.49M | -12.68M | -10.93M | -12.12M | -15.95M | -7.70M | -2.61M | -3.83M | -1.86M | -343.18K | -80.00K | -690.00 |
| EBITDA Ratio | -486.94% | -372.75% | -302.22% | -349.34% | 0.00% | -11,686.38% | -5,270.77% | -4,500.46% | -6,434.51% | -5,979.88% | -3,444.51% | -5,227.91% | -4,135.18% | -3,997.62% | -2,260.14% | -2,106.53% | -2,409.05% | -2,126.50% | -1,440.28% | 69.10% | -293.27% | -101.11% | -425.29% | -360.38% | -435.73% | 0.00% | 0.00% |
| Operating Income | -19.60M | -14.64M | -15.50M | -15.18M | -10.41M | -12.71M | -7.77M | -6.88M | -8.59M | -10.44M | -12.55M | -7.80M | -5.32M | -6.28M | -4.90M | -8.29M | -12.73M | -10.99M | -11.41M | -11.81M | -8.89M | -3.79M | -5.00M | -3.00M | -343.18K | -80.00K | -690.00 |
| Operating Income Ratio | -487.69% | -373.72% | -302.56% | -349.77% | 0.00% | -11,713.74% | -3,862.48% | -5,197.94% | -6,019.19% | -5,901.05% | -3,450.60% | -5,171.41% | -2,849.27% | -4,020.25% | -2,279.38% | -1,935.69% | -2,588.19% | -2,167.55% | -1,496.86% | -446.85% | -385.32% | -209.40% | -628.85% | -581.36% | -435.73% | 0.00% | 0.00% |
| Total Other Income/Expenses | 524.33K | 904.68K | 2.72M | -133.04K | 428.68K | 324.64K | -127.86K | -786.28K | 811.97K | 4.68M | -1.23M | -2.97K | -2.16M | -154.17K | -6.08K | 765.71K | -854.32K | -149.57K | 640.82K | -451.64K | -82.31K | -778.76K | -455.83K | 0.00 | 343.18K | 0.00 | 0.00 |
| Income Before Tax | -19.08M | -13.70M | -12.78M | -15.31M | -10.06M | -12.34M | -8.27M | -7.54M | -7.73M | -5.89M | -13.33M | -7.79M | -5.24M | -6.43M | -4.91M | -7.52M | -13.59M | -11.14M | -11.73M | -24.91M | -9.83M | -4.57M | -5.45M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -474.65% | -349.87% | -249.38% | -352.78% | 0.00% | -11,367.29% | -4,108.75% | -5,696.60% | -5,418.28% | -3,327.87% | -3,664.14% | -5,161.66% | -2,806.90% | -4,118.99% | -2,282.20% | -1,756.87% | -2,762.17% | -2,197.05% | -1,537.92% | -942.61% | -425.88% | -252.40% | -686.23% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 46.09K | 104.46K | 70.01K | -4.13M | -362.19K | -376.03K | -495.44K | 660.21K | -857.25K | -170.98K | -477.34K | -403.28K | -2.42M | 3.76K | 6.08K | -765.71K | 855.98K | 149.57K | 313.10K | 13.10M | 935.82K | 778.76K | 455.83K | 1.14M | 1.33M | 80.00K | 690.00 |
| Net Income | -19.12M | -13.81M | -12.85M | -15.31M | -9.70M | -11.96M | -8.27M | -7.54M | -7.73M | -5.89M | -13.33M | -7.79M | -5.24M | -6.43M | -4.91M | -7.52M | -13.59M | -11.14M | -11.73M | -24.91M | -9.83M | -4.57M | -5.45M | -4.14M | -1.33M | -80.00K | -690.00 |
| Net Income Ratio | -475.79% | -352.54% | -250.75% | -352.78% | 0.00% | -11,020.84% | -4,108.75% | -5,696.60% | -5,418.28% | -3,327.87% | -3,664.14% | -5,161.66% | -2,806.90% | -4,118.99% | -2,282.20% | -1,756.87% | -2,762.17% | -2,197.05% | -1,537.92% | -942.61% | -425.88% | -252.40% | -686.23% | -801.84% | -1,684.00% | 0.00% | 0.00% |
| EPS | -3.14 | -3.41 | -3.20 | -5.41 | -6.50 | -11.66 | -9.29 | -8.48 | -8.69 | -7.02 | -18.68 | -13.79 | -10.92 | -15.59 | -12.94 | -22.31 | -46.67 | -47.49 | -54.94 | -121.74 | -77.86 | -47.77 | -59.82 | -47.99 | -24.00 | -1.05 | -0.01 |
| EPS Diluted | -3.14 | -3.41 | -3.20 | -5.41 | -6.50 | -11.66 | -9.29 | -8.48 | -8.69 | -7.02 | -18.68 | -13.79 | -10.92 | -15.59 | -12.94 | -22.31 | -46.67 | -47.49 | -54.94 | -121.74 | -77.86 | -47.77 | -59.82 | -47.99 | -24.00 | -1.05 | -0.01 |
| Weighted Avg Shares Out | 6.08M | 4.05M | 4.01M | 2.83M | 1.49M | 1.03M | 889.82K | 889.82K | 889.82K | 837.86K | 713.41K | 564.50K | 479.61K | 412.63K | 379.21K | 337.26K | 291.19K | 234.59K | 213.42K | 204.59K | 126.19K | 95.70K | 91.13K | 86.25K | 55.27K | 76.49K | 97.71K |
| Weighted Avg Shares Out (Dil) | 6.08M | 4.05M | 4.01M | 2.83M | 1.49M | 1.03M | 889.82K | 889.82K | 889.82K | 837.86K | 713.41K | 564.50K | 479.61K | 412.63K | 379.21K | 337.26K | 291.19K | 234.59K | 213.42K | 204.59K | 126.19K | 95.70K | 91.13K | 86.25K | 55.27K | 76.49K | 97.71K |
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)...
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity's Company Secretary following her appointment as Chief Financial Officer...
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from...
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron – – Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025 Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System...
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief...
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to...
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®
- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alterity...
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven...
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®
- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ:...
Source: https://incomestatements.info
Category: Stock Reports